Our demonstration of targeting C3 and C5 with CP20 and RaCl is protective in our cell model against α-syn-dependent complement-mediated cytotoxicity supports complement targeting disease-modifying strategies also may hold potential in PD and other synucleinopathies. This evidence concerns the gene C5 and Parkinson disease.